An Apoptosis Methylation Prognostic Signature for Early Lung Cancer in the IFCT-0002 Trial

Purpose: To evaluate prognostic and predictive molecular biomarkers in early-stage non–small cell lung carcinoma (NSCLC) receiving neoadjuvant chemotherapy. Experimental Design: The IFCT-0002 trial compared two neoadjuvant regimens in 528 stages I to II NSCLC patients. DNA extraction of snap-frozen surgical samples taken from 208 patients receiving gemcitabine-cisplatin or paclitaxel-carboplatin regimens allowed for the identification of 3p allelic imbalance, Ras association domain family 1A (RASSF1A) and death-associated protein kinase 1 (DAPK1) promoter methylation, and epidermal growth factor receptor, K-ras, and TP53 mutations. Multivariate analysis identified prognostic and predictive effects of molecular alterations. A Bootstrapping approach was used to assess stability of the prognostic models generating optimism corrected indexes. Results: RASSF1A methylation correlated significantly with shorter disease-free survival (DFS; adjusted HR = 1.88, 95% CI: 1.25–2.82, P = 0.0048) and shorter median overall survival (OS; adjusted HR = 2.01, 95% CI: 1.26–3.20, P = 0.020). A computed bootstrap resampling strategy led to a prognostic model, including RASSF1A, DAPK1, and tumor stage, dividing patients into three prognostic groups, with median OS ranging from 34 months for high-risk patients (HR for death = 3.85, 95% CI: 1.79–6.40) to more than 84 months for moderate (HR = 1.85, 95% CI: 0.97–3.52) and low-risk patients (reference group; P = 0.00044). In addition, RASSF1A methylation predicted longer DFS in patients treated with paclitaxel-carboplatin compared with gemcitabine-cisplatin (adjusted HR = 0.47, 95% CI: 0.23–0.97, Pinteraction = 0.042). Conclusions: Following neoadjuvant chemotherapy, RASSF1A methylation negatively impacted prognosis of early-stage NSCLC. Along with DAPK1 methylation and tumor stage, RASSF1A methylation allowed definition of three subgroups with strikingly different prognosis. Conversely, significantly longer DFS following paclitaxel-based neoadjuvant chemotherapy for patients whose tumors showed RASSF1A methylation suggested its predictive interest in stages I and II NSCLC. Clin Cancer Res; 18(10); 2976–86. ©2012 AACR.

[1]  B. Milleron,et al.  Results of the IFCT 0002 phase III study comparing a preoperative and a perioperative chemotherapy (CT) with two different CT regimens in resectable non-small cell lung cancer (NSCLC). , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Igor Jurisica,et al.  Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  T. Huang,et al.  Distinct Epigenetic Domains Separated by a CTCF Bound Insulator between the Tandem Genes, BLU and RASSF1A , 2010, PloS one.

[4]  S. Davis,et al.  Epigenomic alterations and gene expression profiles in respiratory epithelia exposed to cigarette smoke condensate , 2010, Oncogene.

[5]  J. Hoheisel,et al.  High-Definition DNA Methylation Profiles from Breast and Ovarian Carcinoma Cell Lines with Differing Doxorubicin Resistance , 2010, PloS one.

[6]  J. Coon,et al.  PTEN, RASSF1 and DAPK site‐specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients , 2010, International journal of cancer.

[7]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[8]  M. Gaub,et al.  Detection of K-Ras mutations in tumour samples of patients with non-small cell lung cancer using PNA-mediated PCR clamping , 2009, British Journal of Cancer.

[9]  Richard J Stephens,et al.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  N. Riaz.  DNA methylation in lung cancer. , 2008, The New England journal of medicine.

[11]  B. Milleron,et al.  Use of Ras effector RASSF1A promoter gene methylation and chromosome 9p loss of heterozygosity (LOH) to predict progression-free survival (PFS) in perioperative chemotherapy (CT) phase III trial IFCT-0002 in resectable non-small cell lung cancer , 2008 .

[12]  Steven Piantadosi,et al.  DNA methylation markers and early recurrence in stage I lung cancer. , 2008, The New England journal of medicine.

[13]  Gen Tamura,et al.  Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers. , 2007, Lung cancer.

[14]  H. Donninger,et al.  The RASSF1A tumor suppressor , 2007, Journal of Cell Science.

[15]  J. Pignon,et al.  Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  D. Weisenburger,et al.  Downregulation of Death-Associated Protein Kinase 1 (DAPK1) in Chronic Lymphocytic Leukemia , 2007, Cell.

[17]  A. M. Ishov,et al.  Daxx Shortens Mitotic Arrest Caused by Paclitaxel , 2007, Cell cycle.

[18]  E. Brambilla,et al.  Tumor-Specific Methylation in Saliva: A Promising Biomarker for Early Detection of Head and Neck Cancer Recurrence , 2007, Clinical Cancer Research.

[19]  Jeremy J. W. Chen,et al.  A five-gene signature and clinical outcome in non-small-cell lung cancer. , 2007, The New England journal of medicine.

[20]  L. Stewart,et al.  A Systematic Review and Meta-analysis of the Literature: Chemotherapy and Surgery versus Surgery Alone in Non-small Cell Lung Cancer , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  G. Zalcman,et al.  Routine detection of EGFR mutations in patients with NSCLC: A comparative study of three alternative methods in 105 patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  K. Kelsey,et al.  Homozygous deletion of p16INK4a and tobacco carcinogen exposure in nonsmall cell lung cancer , 2006, International journal of cancer.

[23]  Jie-Oh Lee,et al.  Role of the tumor suppressor RASSF1A in Mst1-mediated apoptosis. , 2006, Cancer research.

[24]  S. Hahn,et al.  Prognostic implication of aberrant promoter hypermethylation of CpG islands in adenocarcinoma of the lung. , 2005, The Journal of thoracic and cardiovascular surgery.

[25]  B. Ng,et al.  The RASSF1A Isoform of RASSF1 Promotes Microtubule Stability and Suppresses Tumorigenesis , 2005, Molecular and Cellular Biology.

[26]  J. Lafitte,et al.  Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature. , 2005, Lung cancer.

[27]  P. Hainaut,et al.  TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. , 2005, Cancer research.

[28]  L. Hutchins,et al.  Methylation Profiling of Archived Non–Small Cell Lung Cancer: A Promising Prognostic System , 2005, Clinical Cancer Research.

[29]  Y. T. Kim,et al.  Can aberrant promoter hypermethylation of CpG islands predict the clinical outcome of non-small cell lung cancer after curative resection? , 2005, The Annals of thoracic surgery.

[30]  Li Mao,et al.  Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Diane D. Liu,et al.  Value of p16INK4a and RASSF1A Promoter Hypermethylation in Prognosis of Patients with Resectable Non–Small Cell Lung Cancer , 2004, Clinical Cancer Research.

[32]  G. Clark,et al.  A Role for the RASSF1A Tumor Suppressor in the Regulation of Tubulin Polymerization and Genomic Stability , 2004, Cancer Research.

[33]  J. Califano,et al.  Death-associated protein kinase promoter hypermethylation in normal human lymphocytes. , 2003, Cancer research.

[34]  Tim Hui-Ming Huang,et al.  Differential distribution of DNA methylation within the RASSF1A CpG island in breast cancer. , 2003, Cancer research.

[35]  Y. Shim,et al.  Relationship of Ras association domain family 1 methylation and K-ras mutation in primary non-small cell lung cancer. , 2003, Cancer research.

[36]  Y. Shim,et al.  Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer. , 2003, Cancer research.

[37]  D. Jaeck,et al.  Genetic heterogeneity in lung and colorectal carcinoma as revealed by microsatellite analysis in plasma or tumor tissue DNA , 2003, Cancer.

[38]  S. Goodman,et al.  Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  J. Minna,et al.  Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  G. Pfeifer,et al.  Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. , 2002, Cancer research.

[41]  T. Tuschl,et al.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells , 2001, Nature.

[42]  J. Minna,et al.  Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. , 2001, Journal of the National Cancer Institute.

[43]  J. Minna,et al.  Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours , 2001, Oncogene.

[44]  F. Khuri,et al.  Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. , 2000, Journal of the National Cancer Institute.

[45]  S. Polak‐Charcon,et al.  DAP kinase links the control of apoptosis to metastasis , 1997, Nature.

[46]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[47]  Y. Benjamini,et al.  More powerful procedures for multiple significance testing. , 1990, Statistics in medicine.

[48]  L. Tanoue.  Cancer Statistics, 2009 , 2010 .

[49]  Paolo Boffetta,et al.  Quantitative analysis of DNA methylation profiles in lung cancer identifies aberrant DNA methylation of specific genes and its association with gender and cancer risk factors. , 2009, Cancer research.

[50]  L. Tanoue.  Prognostic Factors in Resected Stage I Non-Small-Cell Lung Cancer: A Multivariate Analysis of Six Molecular Markers , 2006 .

[51]  Gustavo Droguett,et al.  DAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation , 2000, Nature Cell Biology.

[52]  P. Royston,et al.  Building multivariable prognostic and diagnostic models: transformation of the predictors by using fractional polynomials , 1999 .

[53]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.